1	Real-time RT-PCR Allelic Discrimination Assay for Detection of N501Y Mutation in the		
2	Spike Protein of SARS-CoV-2 Associated with Variants of Concern.		
3	Running Title: Assay for detection of S:N501Y in SARS-CoV-2		
4	Mariana Abdulnoor HBSc ^{a,b,d,e} , AliReza Eshaghi PhD ^{b,e} , Stephen J. Perusini MSc ^b , Antoine		
5	Corbeil MD ^{a,b} , Kirby Cronin BSc ^b , Nahuel Fittipaldi PhD ^{a,b*} , Jessica D. Forbes PhD ^b , Jennifer L		
6	Guthrie PhD ^a , Julianne V. Kus PhD ^{a,b} , Anna Majury PhD ^a , Tony Mazzulli MD ^{a,c} , Roberto G.		
7	Melano PhD ^{a,b} , Romy Olsha MD ^a , Ashleigh Sullivan MPH ^a , Vanessa Tran PhD ^{a,b} , Samir N.		
8	Patel PhD ^{a,b} , Vanessa G. Allen MDCM ^{a,b} , Jonathan B. Gubbay MBBS ^{a,b,d#}		
9	Affiliations:		
10	a. Public Health Ontario, Toronto, Ontario Canada		
11	b. Department of Laboratory Medicine and Pathobiology, University of Toronto,		
12	Toronto, Ontario, Canada		
13	c. Department of Microbiology, Sinai Health/University Health Network, Toronto,		
14	Ontario, Canada		
15	d. Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick		
16	Children, Toronto, Ontario, Canada		
17	e. Co-first authorship: Mariana Abdulnoor, AliReza Eshaghi. Mariana Abdulnoor wrote		
18	up the manuscript, AliReza Eshaghi conducted experiments and wrote up the		
19	manuscript. Order was determined alphabetically by last name		
20	# Corresponding Author, Email address: jonathan.gubbay@oahpp.ca		
21 22 23	*Nahuel Fittipaldi's new address is Université de Montréal, St-Hyacinthe St-Hyacinthe, Québec, Canada		
24			

25 Abstract:

26 The N501Y amino acid mutation caused by a single point substitution A23063T in the spike 27 gene of SARS-CoV2 is possessed by the three most common variants of concern - B.1.1.7, 28 B.1.351, and P.1. A rapid screening tool using this mutation is important for surveillance during 29 the COVID-19 pandemic. 30 We developed and validated a single nucleotide polymorphism real-time reverse transcription 31 polymerase chain reaction assay using allelic discrimination of the spike gene N501Ymutation to 32 screen for potential variants of concern and differentiate them from wild-type SARS-CoV-2. A 33 total of 160 clinical specimens positive for SARS-CoV-2 were characterized as mutant (N501Y) 34 or wild-type by Sanger sequencing and were subsequently tested with the N501Y single 35 nucleotide polymorphism real time reverse transcriptase polymerase chain reaction assay. Our 36 assay compared to sequencing, the gold standard for SNP detection and lineage identification, 37 demonstrated clinical sensitivity of 100% for all 57 specimens displaying N501Y mutant, which 38 were confirmed by Sanger sequencing to be typed as A23063T, including one specimen with 39 mixed signal for wildtype and mutant. Clinical specificity was 100% in all 103 specimens typed 40 as wild-type, with A23063 identified as wild-type by Sanger sequencing. The identification of 41 circulating SARS-CoV-2 lineages carrying an N501Y mutation is critical for surveillance 42 purposes. Current identification methods rely primarily on Sanger sequencing or whole genome 43 sequencing which are time-consuming, labor-intensive and costly. The assay described herein is 44 an efficient tool for high-volume specimen screening for SARS-CoV-2 VOCs and for selecting specimens for confirmatory Sanger or whole genome sequencing. 45 46

- .-
- 47

48 Introduction:

49	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the viral etiology of the
50	coronavirus disease 2019 (COVID-19) pandemic. Several SARS-CoV-2 variants of concern
51	(VOC) have been identified which are associated with increased transmissibility, increased
52	virulence, changes in clinical disease presentation and decreased effectiveness of public health
53	measures, diagnostics, vaccines, and therapeutics (1). In 2020, three novel VOCs of SARS-
54	CoV-2 emerged independently (2-4).
55	
56	The VOC first detected in the UK represents the B.1.1.7 lineage (also known as 20I/501Y.V1
57	and VOC202012/010) and contains three key mutations in S gene 69-70del, N501Y and P681H.
58	Recently, E484K has been observed in some B.1.1.7 genome sequences (5). B.1.1.7 is associated
59	with increased transmissibility of 50-70% (6), and increased disease severity and risk of death
60	(7). Cases of B.1.1.7 lineage have been found in 114 countries (8). In Ontario, Canada, 2,165
61	cases of B.1.1.7 have been confirmed as of April 5, 2021(9).
62	
63	A second SARS-CoV-2 VOC representing the B.1.351 lineage (also known as 20H/501Y.V2
64	and VOC-202012/02) emerged in October 2020 in South Africa, and rapidly has become the
65	dominant circulating strain in that country (3). This VOC has multiple mutations in the receptor
66	binding domain (RBD) of the S protein, including K417N, E484K, and N501Y. The B.1.351
67	lineage is associated with increased transmissibility (10) and immune evasion (11,12). It is
68	unknown how this VOC influences disease severity, hospitalizations and deaths. B.1.351 has
69	been detected in 68 countries (13) including Canada, where in Ontario there are 71 confirmed
70	cases, as of April 5, 2021(9).

7	1
/	T

72	A third emerging VOC is the P.1 lineage (also known as B.1.1.28.1, 20J/501Y.V3, and VOC-
73	202101/02), first detected in Japan from travelers returning from Brazil (14). This VOC shares
74	the S gene N501Y single nucleotide polymorphism (SNP) with B.1.1.7 and the E484K SNP with
75	B.1.351; however, all three lineages arose independently (4). The P.1 lineage may have higher
76	inherent transmissibility compared to previous lineages (14). This lineage is associated with
77	antigenic escape (12). The P.1 lineage has been identified in 36 countries (15) including Canada,
78	where there are 106 confirmed cases in Ontario as of April 5, 2021 (9).
79	
80	These SARS-CoV-2 VOCs will likely hamper public health efforts to contain the spread of the
81	virus. Thus, surveillance is important to control the spread of these lineages. Current methods
82	rely on genome sequencing, either by Sanger sequencing or whole genome sequencing (WGS).
83	These approaches, although of high accuracy, are labour-intensive and are not amenable to rapid
84	turnaround times as they require extensive laboratory processing and bioinformatic analysis.
85	They usually take several days to complete, therefore testing capacity is quickly outpaced as the
86	number of specimens to be analyzed increases with transmission.
87	
88	The use of real-time reverse transcription PCR (rRT-PCR) to detect SNPs of relevance would
89	facilitate rapid preliminary identification of potential VOCs and initiation of public health
90	measures. Herein, we report a laboratory developed SNP rRT-PCR protocol to detect the
91	presence of N501Y, which can act as a screening tool for the three circulating VOCs in Ontario
92	as they all share this SNP. Specimens with N501Y detected are subsequently submitted for WGS
93	to confirm the presence of a VOC and identify the SARS-CoV-2 VOC lineage.

94

95 Methods:

- 96 Clinical Specimens:
- 97 Public Health Ontario (PHO) Laboratory is the reference microbiology laboratory for the
- 98 province of Ontario, Canada. As part of the response to detect VOCs in Ontario, PHO
- 99 Laboratory developed indications for VOC screening, which were similar to Canadian guidelines
- 100 (16). Clinical specimens that met these criteria with a cycle threshold (Ct) value ≤ 30 underwent
- 101 Sanger sequencing of a 698 bp (nucleotide positions 22516 to 23214) S gene fragment, which
- 102 includes the locations of key RBD mutations (K417N/T, E484K, N501Y). Specimens with
- 103 mutations detected underwent further sequencing to confirm if a VOC was present. In addition, a

104 subset of all SARS-CoV-2 positive specimens underwent WGS as part of the provincial genomic

105 surveillance program, which included VOC screening.

106

107 A convenience sample of 160 SARS-CoV-2 positive clinical specimens collected between

108 November 20, 2020 and January 20, 2021, submitted to PHO Laboratory from across the

109 province, that had undergone VOC screening by partial S gene sequencing, as described above,

110 were used in the optimization and validation of the assay. No clinical information was available

111 when sequencing was conducted. However, the presence of N501Y was known prior to running

- 112 specimens in our assay as it was previously sequenced. All SARS-CoV-2 positive specimens
- 113 with N501Y available at PHO Laboratory were included. Specimen types included

114 nasopharyngeal swabs, throat swabs, and bronchoalveolar lavage fluid.

115

116 **rRT-PCR Design and Optimization:**

117	Primer and probe sequences were selected using an alignment of spike nucleotide sequences of a
118	wild-type SARS-CoV2 reference genome (GenBank accession: MN908947.3) and a
119	representative of the VOC B.1.1.7 lineage (GSAID accession: EPI_ISL_601443). Selected
120	primer and probe sequences were aligned to 9000 gene sequences downloaded from GISAID
121	with submission date between December 1, 2020 through December 6, 2020 to ensure they were
122	targeting a conserved region. In addition, a BLAST search of the primer and probe sequences
123	against the whole genome of the reference sequence (MN908947.3) was conducted to ensure the
124	absence of homology to other parts of the SARS-CoV-2 genome. Primers and probes selected for
125	the detection of SNP A23063T are reported in Supplementary Table 1. Primer and probes were
126	synthesized by LGC, Biosearch Technologies (Middlesex, United Kingdom). Optimization was
127	performed using previously characterized wild-type and B.1.1.7 specimens. No B.1.351 or P.1
128	lineage SARS-CoV-2 were detected in Ontario at the time of assay development.
129	
130	An additional smaller validation was conducted using primers and probes from a second vendor,
131	Thermo Fisher Scientific (Massachusetts, United States), to allow redundancy of reagent
132	suppliers.
133	
134	Total Nucleic Acid Extraction:
135	Specimens underwent nucleic acid extraction using either Perkin Elmer chemagic [™] 360
136	automated systems (PerkinElmer, Massachusetts, United States) (input volume 300 μ l; eluate

137 volume 60 µl) or MGISP-960RS platform (MGI Tech Co., Guangdong, China) (input volume

138 180 µl; eluate volume 45 µl) according to the manufacturer's recommendations.

140 N501Y SNP rRT-PCR Assay:

The PCR amplification was performed using the Taqpath[™] 1-Step Multiplex Master Mix on the
Applied Biosystems[™] QuantStudio[™] 5 Real-Time PCR system (Thermo Fisher Scientific,
Massachusetts, United States).

144

A total volume of 10µl reaction mix contained 2.5µl of 4X TaqPathTM 1-Step Multiplex Master 145 146 Mix, 1.0µl of primer mix, 1.0µl of probe mix, 2.5µl of RNase-free water, and 3µl of viral RNA 147 extract. The default thermocycling profile suggested for 4X TaqPathTM 1-Step Multiplex Master 148 Mix was used including 20 minutes at 25° C, 10 minutes at 53°C, 2 minutes at 95°C and 45 149 cycles of 95°C for 3 seconds then 60°C for 30 seconds. The controls used in each run were an 150 extraction negative control that consisted of a nuclease-free water processed along with SARS-151 CoV-2 specimens during the extraction process, a PCR negative control that consisted of 152 nuclease-free water in place of nucleic acid in the reaction mix, and a positive RNA 153 amplification control consisting of combined wild-type and B.1.1.7 SARS-CoV-2 RNA obtained 154 from clinical specimens positive by in-house end-point PCR and sequencing. During 155 optimization, it was determined that nonspecific signals occurred above a Ct of 37, therefore 156 only results with $Ct \leq 37$ were considered positive for either probe target. The assay does not 157 have an indeterminate range. The time interval between sequencing and running the N501Y rRT-158 PCR assay ranged from one to 14 days. 159

160 PCR Amplification and Sequencing of Partial Spike Gene:

161 Sanger sequencing was chosen as the comparator method as it is a highly accurate methodology

162 to determine the presence of SNPs, is the gold standard for identifying SNPs, and was the

163	method in use at PHO Laboratory for VOC detection. A detailed explanation of the Sanger
164	sequencing protocol used is provided in Supplementary appendix A. Specimens with Ct values
165	≤35 with a good quality Sanger chromatogram, containing evenly-spaced peaks each with one
166	colour, and the least amount of baseline noise, were considered positive. Sanger sequencing
167	failed when Ct values were >35 and the chromatogram contained mixed bases and was messy.
168	
169	Validation:
170	Primary outcome measures were clinical sensitivity, clinical specificity, and precision.
171	
172	Accuracy – Clinical Sensitivity and Specificity
173	A panel of 160 SARS-CoV-2 positive clinical specimens that had been characterized by partial
174	Sanger sequencing of the S gene were used for validation of the N501Y SNP assay. The result
175	obtained by our rRT-PCR N501Y SNP assay was compared to the known sequence results
176	previously obtained by partial S gene sequencing and used to calculate sensitivity and specificity.
177	Sensitivity of >90% and specificity >95% were considered acceptable.
178	
179	Intra-run repeatability
180	Intra-run repeatability was evaluated by running three replicates of 10 N501Y VOCs (including
181	1 with a mixed population) and 5 wild-type samples in the same rRT-PCR run and comparing Ct
182	values across the replicates. The threshold for acceptance between runs was a Ct difference of
183	<3.3.
184	

185 Inter-run reproducibility

Inter-run reproducibility was evaluated by rerunning the panel used for intra-run repeatability on
a second day. This panel was also sent out to six other microbiology laboratories in Ontario to
validate the assay prior to implementation. The threshold for acceptance was >95% agreement
between labs.

190

191 Ethical Statement:

192 The PHO Ethics Review Board has determined that this project did not require research ethics

193 committee approval, as it describes analyses that were completed at PHO Laboratory as part of

194 routine clinical respiratory testing and surveillance during the COVID-19 pandemic in Ontario

and are, therefore, considered public health practice and exempt from this requirement.

196

197 **Results:**

198 Accuracy - Clinical Sensitivity and Specificity:

199 To analyze the performance of the N501Y SNP assay, a panel of 160 specimens including 57

200 specimens with N501Y detected by Sanger sequencing, and 103 wild-type were tested. One of

201 the 57 N501Y positive specimens contained a mixed result on Sanger sequencing, indicating the

202 presence of both wild-type and mutant strains. All specimens with a known A23063T

substitution in the Sanger chromatogram produced a positive signal for N501Y with the rRT-

204 PCR SNP assay (57/57, 100%), and were confirmed to be B.1.1.7 lineage by Sanger sequencing

analysis. All samples with known A23063 wild-type characterization by Sanger showed positive

signal for wild-type with the rRT-PCR SNP assay (103/103, 100%). The positive predictive

207 value was 100%% (57/57) and the negative predictive value was 100% (103/103) (**Table 1**).

209	The mean E gene and N501Y SNP rRT-PCR assay Ct values of all VOC specimens in this study
210	were 19.15 (S.D. 3.76) and 21.88 (S.D. 3.80), respectively. The mean Ct values of E gene and
211	N501 SNP rRT-PCR for wild-type specimens were 20.87 (S.D. 5.38) and 23.75 (S.D. 5.52),
212	respectively. (Supplementary Table 2).
213	
214	Comparison of two primer and probe sets:
215	Our N501Y SNP assay was validated using primer and probe sets from two vendors, LGC,
216	Biosearch Technologies (Middlesex, United Kingdom) and Thermo Fisher Scientific
217	(Massachusetts, United States). A subset of 87 specimens, including 14 mutants, 72 wild-type
218	and one mixed population were tested (Table 1). We observed comparable results for both
219	primer and probe sets, as there were no significant differences in average Ct values or number of
220	N501Y specimens detected.
221	
222	Precision – intra-run repeatability and inter-run reproducibility:
223	The analysis of intra-run repeatability was done with a panel of nine N501Y samples, five wild-
224	type, one mixed N501Y/N501 sample, and five SARS-CoV-2 negative samples. The panel was
225	run on three replicates. The results show 100% agreement (Supplementary Table 3) with an
226	average Ct 26.17 (average SD 0.19, average coefficient of variation 0.71%) for the mutant
227	specimens and average Ct 26.76 (average SD 0.16, average coefficient of variation 0.6%) for
228	wild-type specimens.
229	
230	The analysis of inter-run reproducibility was done with replicates of a panel of nine N501Y

samples, five wild-type samples, one mixed N501Y/N501 sample, and five negative samples.

Among the 10 runs obtained from seven laboratories, the results showed 100% agreement with

an average Ct 26.04 (SD 0.98, coefficient of variation 4%) for mutant specimens and an average

234 Ct 27.39 (SD 1.29, coefficient of variation 5%) for wild-type specimens.

235

236 **Discussion:**

237 Here we describe the validation of a N501Y SNP rRT-PCR assay to provide rapid screening of

238 SARS-CoV-2 positive specimens for VOCs. Currently, three VOCs (B1.1.7, B.1.351 and P.1)

are circulating in Ontario and surveillance of these VOCs is of considerable public health

240 importance. The World Health Organization recommends VOC surveillance to help control the

spread of VOCs (1). In our workflow, positive SARS-COV-2 specimens are screened for the

242 N501Y SNP using the described rRT-PCR assay then potentially submitted for WGS to confirm

243 VOC identification and determine the VOC lineage. There were no adverse events from

244 performing the N501Y SNP rRT-PCR assay as individuals had already been classified as having

the mutation or not based on previous sequencing. Our assay is efficient, and clinically validated

with a high degree of sensitivity and specificity for detection of the N501Y SNP.

247

248 Sanger sequencing or WGS of VOCs require longer turnaround times, are expensive, and some 249 regions may not have access to sequencing facilities or the ability to scale-up their sequencing 250 capabilities. A two-factor screening process for B.1.1.7 detection has been employed to aid with 251 surveillance efforts (17). The protocol detects the 69-70del in the S gene of B.1.1.7 as this 252 deletion causes S-gene target failure (SGTF) in certain assays (e.g. Thermo Fisher's TaqPath 253 COVID-19 Combo Kit). Once SGTF is detected, specimens are sequenced by WGS. SGTF has 254 been used as a proxy for the B.1.1.7 VOC (6). This method is limited to detecting VOCs carrying 255 69-70del. A multiplex rRT-PCR to screen for VOC was published by Vogel et al. (18) that

256	targets the aa3675-3677 deletion in ORF1a gene as well as the aa69-70del in the S gene. The
257	ORF1a deletion of aa3675-3677 is present in B.1.17, B.1.351, and P.1 and the aa69-70del in S
258	gene is used to differentiate B.1.17 from B.1351 and P.1. However, the ORF1a deletion is not
259	found in all B.1.351 VOCs, as there is a monophyletic clade that does not contain this deletion.
260	Another group (19) published a rRT-PCR assay to detect only the N501Y SNP and requires a
261	melting curve to confirm the specimens as wild-type if the test is negative. Our procedure differs
262	as it is able to detect both the wild-type and the SNP, avoiding the additional step of analyzing
263	melting-curves and thus providing easier interpretation of the results.
264	
265	To understand the provincial prevalence of VOCs in Ontario, the majority of SARS-CoV-2
266	positive specimens reported on January 20, 2021 across the province were sent for screening
267	using our rRT-PCR N501Y SNP assay (20). Our rRT-PCR N501Y SNP assay has now been
268	instituted for surveillance testing across Ontario, allowing notification to public health at least
269	one to seven days earlier than relying on Sanger sequencing or WGS. On March 11, 2021, 1,138
270	specimens were screened with our N501Y rRT-PCR assay, 897/899 (99.8%) specimens that
271	tested positive for N501Y SNP were confirmed through WGS and 238/239 (99.6%) were
272	confirmed wildtype through WGS (data extracted from PHO laboratory information system).
273	Using this assay, we've now documented a rapid rise in VOC cases with roughly 60% of cases
274	on April 5, 2021 identified as VOC or containing N501Y and/or E484K SNPs (9).
275	
276	Because our assay only detects the N501Y SNP, new emerging lineages that do not carry this
277	SNP, such as B.1.525, will be missed (21). The assay is also unable to differentiate between
278	VOCs that share the N501Y SNP; therefore, an additional sequencing step is required to

279 delineate the lineage. An additional SNP assay target detecting E484K was incorporated into this 280 assay in a multiplex format as of March 22, 2021, and assays to detect E417T/N S gene 281 mutations are currently under development in our laboratory as these could provide further 282 characterization of currently known VOCs without requirement of WGS. Even with additional 283 targets, definitive lineage identification is not possible based on SNP assays alone and requires 284 sequencing. Our validation was conducted with specimens characterized as B.1.1.7 but when 285 implemented as a screening tool we were able to detect B.1.351 and P.1 VOCs. Our validation 286 dataset contained a small sample size of 57 positive specimens; however, clinical sensitivity and 287 specificity were further confirmed in our data review post-implementation. A limit of detection 288 was not performed, however, comparison of rRT-PCR SNP Ct values to E gene Ct values using 289 the Corman et al (22) assay, shows the SNP assay is approximately 1 log less sensitive (3-4 290 cycles higher). We did not conduct analytical specificity tests with a cross reactivity panel due to 291 limited availability of SARS-CoV-2 VOC strains. In our analysis we did not assess baseline 292 demographics, clinical characteristics of the patients and severity of disease, as limited 293 information is provided to PHO Laboratory, which provides testing as a reference laboratory. 294 Our assay is not intended for diagnostic purposes, but rather as a screening tool to aid with faster 295 identification of VOCs through differentiation of N501 and N501Y. 296

297 Our assay is a quick and simple tool that can be applied to screening SARS-CoV-2 positive

298 specimens from priority groups at greater risk for VOC infection such as international travellers,

suspected SARS-CoV-2 reinfection, infection post COVID-19 vaccination, and outbreaks.

300 Ontario is screening all positive specimens, which can be in excess of 1000 specimens per day,

301 and the N501Y SNP rRT-PCR assay has allowed us to screen a high volume of specimens. Due

302	to high specificity and positive predictive value, any specimen that is N501Y positive can be
303	presumed to be a VOC while awaiting characterization by WGS. Early, high-throughput
304	screening with PHO Laboratory's N501Y screening assay allows effective public health
305	measures to be put in place to limit the spread of VOCs in the community.
306	
307	Conflict of Interest Disclosure: All authors declare no competing interests.
308	
309	Financial Disclosure: This study was funded by PHO Laboratory.
310	
311	Acknowledgement: We acknowledge the collaboration of members of the Ontario Provincial
312	COVID-19 Diagnostic Network. We acknowledge the staff of Virus Detection and Molecular
313	Diagnostics, Public Health Ontario Laboratory, for diagnostic testing and N501Y screening of
314	SARS-CoV-2 specimens. We thank the Public Health Ontario Laboratory research group for
315	conducting SARS-CoV-2 whole genome sequencing.
316	
317	
318	
319	
320	
321	
322	
323	
324	

325 **References:**

326	1.	COVID-19 Weekly epidemiological update. World Health Organization. Published
327		February 25, 2021. https://www.who.int/publications/m/item/covid-19-weekly-
328		epidemiological-update
329	2.	Rambaut A, Loman N, Pybus O, et al. Preliminary genomic characterisation of an
330		emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations.
331		Virological. Published December 2020. https://virological.org/t/preliminary-genomic-
332		characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-
333		of-spike-mutations/563.
334	3.	Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new
335		severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with
336		multiple spike mutations in South Africa. medRxiv. 2020.
337		http://doi.org/10.1101/2020.12.21.20248640.
338	4.	Faria NR, Claro IM, Candido D, et al. Genomic characterisation of an emergent
339		SARS-CoV-2 lineage in Manaus: preliminary findings. Virological. Published Jan 12,
340		2021. Accessed February 6, 2021. https://virological.org/t/genomic-characterisation-
341		of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586.
342	5.	Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in
343		England: Insights from linking epidemiological and genetic data. medRxiv. 2021.
344		https://doi.org/10.1101/2020.12.30.20249034.
345	6.	Davies NG, Barnard RC, Jarvis CI, Kucharski AJ, Munday J, Pearson CAB, et al.
346		Estimated transmissibility and severity of novel SARS-CoV-2 variant of concern

347	202012/01 in England. medRxiv. 2020.
348	https://www.medrxiv.org/content/10.1101/2020.12.24.20248822v1
349	7. Horby P, Huntley C, Davies N, Edmunds J, Ferguson N, Medley G, Semple C.
350	NERVTAG note on B.1.1.7 severity. GOV.UK. Published January 21, 202.
351	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme
352	nt_data/file/961037/NERVTAG_note_on_B.1.1.7_severity_for_SAGE_771pdf
353	8. B.1.1.7. SARS-CoV-2 Lineages. Published February 20, 2021. https://cov-
354	lineages.org/global_report_B.1.1.7.html
355	9. Daily epidemiologic summary: COVID-19 in Ontario: January 15, 2020 to April 5,
356	2021. Ontario Agency for Health Promotion and Protection (Public Health Ontario).
357	https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-daily-epi-
358	<u>summary-report.pdf?la=en</u>
358 359	summary-report.pdf?la=en 10. Risk Assessment: Risk related to the spread of new SARS-CoV-2 variants of concern
359	10. Risk Assessment: Risk related to the spread of new SARS-CoV-2 variants of concern
359 360	10. Risk Assessment: Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA-first update. European Centre for Disease Prevention and Control.
359 360 361	 Risk Assessment: Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA-first update. European Centre for Disease Prevention and Control. Published January 21, 2021. https://www.ecdc.europa.eu/en/publications-data/covid-
359 360 361 362	 10. Risk Assessment: Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA-first update. European Centre for Disease Prevention and Control. Published January 21, 2021. https://www.ecdc.europa.eu/en/publications-data/covid- 19-risk-assessment-spread-new-variants-concern-eueea-first-update
 359 360 361 362 363 	 10. Risk Assessment: Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA-first update. European Centre for Disease Prevention and Control. Published January 21, 2021. https://www.ecdc.europa.eu/en/publications-data/covid- 19-risk-assessment-spread-new-variants-concern-eueea-first-update 11. Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et
 359 360 361 362 363 364 	 10. Risk Assessment: Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA-first update. European Centre for Disease Prevention and Control. Published January 21, 2021. https://www.ecdc.europa.eu/en/publications-data/covid- 19-risk-assessment-spread-new-variants-concern-eueea-first-update 11. Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor
 359 360 361 362 363 364 365 	 10. Risk Assessment: Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA-first update. European Centre for Disease Prevention and Control. Published January 21, 2021. https://www.ecdc.europa.eu/en/publications-data/covid- 19-risk-assessment-spread-new-variants-concern-eueea-first-update 11. Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. <i>Nat Med.</i> 2021;<u>https://doi.org/10.1038/s41591-021-01285-x</u>

369	13. B.1.351. SARS-CoV-2 Lineages. Published February 20, 2020. https://cov-
370	lineages.org/global_report_B.1.351.html
371	14. Sabino EC, Buss LF, Carvalho MPS, Prete Jr CA, Crispim MAE, Fraiji NA, et al.
372	Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. The
373	Lancet. 2021; 6736(21)00183-00185. https://doi.org/10.1016/ S0140-6736(21)00183-
374	5.
375	15. P.1. SARS-CoV-2 Lineages. Published February 20, 2021. https://cov-
376	lineages.org/global_report_P.1.html
377	16. SARS-CoV-2 (COVID-19 Virus) Variant of Concern (VoC) Surveillance. Ontario
378	Agency for Health Protection and Promotion (Public Health Ontario).
379	https://www.publichealthontario.ca/en/laboratory-services/test-information-
380	index/covid-19-voc
381	17. Bal A, Destras G, Gaymard A, Stefic K, Marlet J, Eymieux S, et al. Two-step
382	strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and
383	other variants with spike deletion H69–V70, France, August to December 2020.
384	Eurosurveillance. 2021;26(3):pii=2100008. https://doi.org/10.2807/1560-
385	<u>7917.ES.2021.26.3.2100008</u>
386	18. Vogels CBF, Breban M, Alpert T, Petrone ME, Watkins AE, Hodcroft EB, et al. PCR
387	assay to enhance global surveillance for SARS-CoV-2 variants of concern. medRxiv,
388	2021. https://doi.org/10.1101/2021.01.28.21250486.
389	19. Durner J, Burggraf S, Czibere L, Tehrani A, Watts DC, Becker M. Fast and cost-
390	effective screening for SARS-CoV-2 variants in a routine diagnostic setting. Dental
391	Materials. 2021. https://doi.org/10.1016/j.dental.2021.01.015.

392	20. Summary report: SARS-CoV-2 variants of concern: results of point-prevalence study.
393	Ontario Agency for Health Protection and Promotion (Public Health Ontario).
394	https://www.publichealthontario.ca/-/media/documents/ncov/voc/2021/02/sars-cov-2-
395	variants-point-prevalence.pdf?la=en
396	21. B.1.525. SARS-CoV-2 Lineages. Published February 20, 2021. https://cov-
397	lineages.org/global_report_B.1.525.html
398	22. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al.
399	Detection of 2019 novel coronavirus (2019-nCOV) by real-time RT-PCR.
400	Eurosurveillance. 2020;25(3):pii=2000045. https://doi.org/10.2807/1560-
401	<u>7917.ES.2020.25.3.2000045</u>
402	
403 404 405	
405 406 407	
408	
409 410	
411	
412	
413 414	
415	
416	
417	
418 419	
419	
421	
422	
423	
424	
425	
426	

Tables: 427

428

- 429 Table 1: Summary of accuracy testing data for PHO Laboratory SARS- CoV-2 N501Y SNP
- 430 rRT-PCR assay

	Sanger Mutant	Sanger Wild-type	Total
SNP (N501Y) detected	57	0	57
SNP (N501) not	0	103	103
detected			
Total	57	103	160

431 There was one specimen with a mixed population of wild-type and mutant, this specimen was

432 counted as positive for N501Y.

- 434 Table 2: Results of validation experiments with primer and probe sets from two vendors, LGC
- 435 Biosearch Technologies and Thermo Fisher Scientific.

	LGC Biosearc	h Technologies	Thermo Fish	er Scientific
	Wild-type (n=72)	Mutant (n=14)	Wild-type (n=72)	Mutant (n=14)
Average Ct				
Value (S.D.)	27.44 (6.86)	22.11 (6.92)	27.18 (6.80)	22.75 (7.14)

Median Ct				
Value	27.43	21.41	27.07	21.82

- 437 Supplementary Table 1: Primers and probes used in the PHO Laboratory SARS-CoV-2 N501Y
- 438 SNP rRT-PCR assay and Sanger sequencing

Name	Sequence (5'-3')	Position	Final Concentration (nM)
SNP assay primers and probes			
501F	GAAGGTTTTAATTGTTACTTT C	23012- 23033	1000
501R	AAACAGTTGCTGGTGCATGT	23116- 23136	1000
FAM-Y501 (T23063)	CCAACCCACT <i>T</i> ATGGTGTTG	23053- 23072	250
HEX-N501 (A23063)	CCAACCCACTAATGGTGTTG		500

S gene fragment RT-PCR and sequencing primers			
VOCF	AGAGTCCAACCAACAGAATC	22517-	400
	TATTGT	22542	
VOCR	ACACCTGTGCCTGTTAAACCA	23192-	400
	Т	23214	

- 440 Supplementary Table 2: Individual specimen cycle threshold (Ct) values for E gene (22) and
- 441 PHO Laboratory rRT-PCR N501Y assay.

Specimen ID	E gene Ct	SNP	assay	ssay SNP Sanger Sequencing results		J 1		Result
	Ct			icsuits	K417N	E484K	N501 Y	
		N501	N501 Y		G2281 3T	G2301 2A	A2306 3T	
1	18.81	22	ND ^a	Neg	G	G	A	Wild-type
2	22.93	27	ND	Neg	G	G	А	Wild-type
3	23.33	26.9	ND	Neg	G	G	А	Wild-type
4	15.08	17.8	ND	Neg	G	G	А	Wild-type
5	18.16	21.6	ND	Neg	G	G	А	Wild-type
6	19.37	22.3	ND	Neg	G	G	А	Wild-type
7	13.04	16.7	ND	Neg	G	G	А	Wild-type
8	15.03	19	ND	Neg	G	G	А	Wild-type

9	24.14	27.7	ND	Neg	G	G	Α	Wild-type
10	29.78	33.4	ND	Neg	G	G	А	Wild-type
11	19.22	22.9	ND	Neg	G	G	А	Wild-type
12	28.95	32.1	ND	Neg	G	G	A	Wild-type
13	20.24	ND	24.9	Pos	G	G	Т	N501Y
14	15.73	ND	20.4	Pos	G	G	Т	N501Y
15	18.29	ND	22.2	Pos	G	G	Т	N501Y
16	19.00	ND	22.9	Pos	G	G	Т	N501Y
17	18.24	ND	22.5	Pos	G	G	Т	N501Y
18	22.59	ND	26.7	Pos	G	G	Т	N501Y
19	18.97	ND	22.7	Pos	G	G	Т	N501Y
20	14.6	18.3	ND	Neg	G	G	A	Wild-type
21	9.1	12.4	ND	Neg	G	G	A	Wild-type
22	18.9	22.7	ND	Neg	G	G	A	Wild-type
23	13.3	16.9	ND	Neg	G	G	А	Wild-type
24	25.4	ND	29.4	Pos	G	G	Т	N501Y
25	12.8	15.9	ND	Neg	G	G	А	Wild-type
26	17.1	20.8	ND	Neg	G	G	А	Wild-type
27	17.2	ND	21.1	Pos	G	G	Т	N501Y
28	17.7	ND	22.1	Pos	G	G	Т	N501Y
29	27.9	ND	32.2	Pos	G	G	Т	N501Y
30	22.4	ND	26.6	Pos	G	G	Т	N501Y
31	12.7	ND	17	Pos	G	G	Т	N501Y
32	13.2	ND	18.5	Pos	G	G	Т	N501Y
33	34.90	35.8	ND	Neg	G	G	A	Wild-type

34	27.10	29.9	ND	Neg	G	G	А	Wild-type
35	19.97	22.0	ND	Neg	G	G	А	Wild-type
36	23.65	25.9	ND	Neg	G	G	А	Wild-type
37	28.23	30.5	ND	Neg	G	G	А	Wild-type
38	24.89	28.8	ND	Neg	G	G	А	Wild-type
39	23.13	25.6	ND	Neg	G	G	А	Wild-type
40	19.35	22.4	ND	Neg	G	G	А	Wild-type
41	24.49	26.9	ND	Neg	G	G	А	Wild-type
42	16.30	19.1	ND	Neg	G	G	А	Wild-type
43	30.41	33.3	ND	Neg	G	G	А	Wild-type
44	21.20	23.8	ND	Neg	G	G	А	Wild-type
45	26.96	29.7	ND	Neg	G	G	А	Wild-type
46	27.99	30.4	ND	Neg	G	G	А	Wild-type
47	25.96	28.6	ND	Neg	G	G	А	Wild-type
48	23.29	25.8	ND	Neg	G	G	А	Wild-type
49	31.79	33.7	ND	Neg	G	G	А	Wild-type
50	20.76	23.4	ND	Neg	G	G	А	Wild-type
51	21.56	24.8	ND	Neg	G	G	А	Wild-type
52	22.73	24.7	ND	Neg	G	G	А	Wild-type
53	17.08	19.5	ND	Neg	G	G	А	Wild-type
54	16.34	18.8	ND	Neg	G	G	А	Wild-type
55	27.65	30.3	ND	Neg	G	G	А	Wild-type
56	18.93	21.3	ND	Neg	G	G	А	Wild-type
57	21.52	24.3	ND	Neg	G	G	А	Wild-type
58	18.10	21.0	ND	Neg	G	G	А	Wild-type
·	-	•		•	•		•	·

16.46	19.0	ND	Neg	G	G	A	Wild-type
19.09	21.7	ND	Neg	G	G	А	Wild-type
20.80	23.6	ND	Neg	G	G	А	Wild-type
21.42	ND	23.7	Pos	G	G	Т	N501Y
21.7	24.7	ND	Neg	G	G	A	Wild-type
20.1	22.7	ND	Neg	G	G	А	Wild-type
17.6	20.1	ND	Neg	G	G	A	Wild-type
22.8	25.7	ND	Neg	G	G	A	Wild-type
19.8	22.6	ND	Neg	G	G	A	Wild-type
19.7	22.1	ND	Neg	G	G	А	Wild-type
16.8	19.3	ND	Neg	G	G	A	Wild-type
18.8	21.3	ND	Neg	G	G	А	Wild-type
19.9	22.4	ND	Neg	G	G	А	Wild-type
23.6	ND	25.6	Pos	G	G	Т	N501Y
24.7	ND	27.0	Pos	G	G	Т	N501Y
22.1	ND	24.1	Pos	G	G	Т	N501Y
17.0	ND	18.8	Pos	G	G	Т	N501Y
21.9	ND	23.2	Pos	G	G	Т	N501Y
24.3	26.5	ND	Neg	G	G	А	Wild-type
17.33	ND	20.12	Pos	G	G	Т	N501Y
18.23	ND	21.74	Pos	G	G	Т	N501Y
22.37	ND	24.91	Pos	G	G	Т	N501Y
13.54	18.98	ND	Neg	G	А	А	Wild-type
19.63	ND	22.08	Pos	G	G	Т	N501Y
23.34	ND	25.60	Pos	G	G	Т	N501Y
	19.09 20.80 21.42 21.7 20.1 17.6 22.8 19.8 19.7 16.8 18.8 19.9 23.6 24.7 22.1 17.0 21.9 24.3 17.33 18.23 22.37 13.54 19.63	19.0921.720.8023.621.42ND21.724.720.122.717.620.122.825.719.822.619.722.116.819.318.821.319.922.423.6ND24.7ND24.7ND24.7ND17.0ND21.9ND24.326.517.33ND18.23ND13.5418.9819.63ND	19.0921.7ND20.8023.6ND21.42ND23.721.724.7ND20.122.7ND17.620.1ND22.825.7ND19.822.6ND19.722.1ND16.819.3ND18.821.3ND19.922.4ND23.6ND25.624.7ND25.624.7ND24.117.0ND18.821.9ND23.224.326.5ND17.33ND20.1218.23ND21.7422.37ND24.9113.5418.98ND19.63ND22.08	19.09 21.7 ND Neg 20.80 23.6 ND Neg 21.42 ND 23.7 Pos 21.7 24.7 ND Neg 20.1 22.7 ND Neg 20.1 22.7 ND Neg 17.6 20.1 ND Neg 17.6 20.1 ND Neg 19.8 22.6 ND Neg 19.7 22.1 ND Neg 19.8 21.3 ND Neg 19.9 22.4 ND Neg 19.9 22.4 ND Neg 19.9 22.4 ND Neg 23.6 ND 25.6 Pos 24.7 ND 27.0 Pos 21.9 ND 23.2 Pos 17.0 ND 18.8 Pos 21.9 ND 23.2 Pos 24.3 26.5	19.09 21.7 ND Neg G 20.80 23.6 ND Neg G 21.42 ND 23.7 Pos G 21.7 24.7 ND Neg G 20.1 22.7 ND Neg G 20.1 22.7 ND Neg G 17.6 20.1 ND Neg G 17.6 20.1 ND Neg G 19.8 25.7 ND Neg G 19.8 22.6 ND Neg G 19.7 22.1 ND Neg G 19.8 22.6 ND Neg G 18.8 19.3 ND Neg G 19.9 22.4 ND Neg G 23.6 ND 25.6 Pos G 24.7 ND 25.6 Pos G 17.0 ND 24.1	19.09 21.7 ND Neg G G 20.80 23.6 ND Neg G G 21.42 ND 23.7 Pos G G 21.42 ND 23.7 Pos G G 21.7 24.7 ND Neg G G 20.1 22.7 ND Neg G G 17.6 20.1 ND Neg G G 17.6 20.1 ND Neg G G 19.8 22.6 ND Neg G G 19.7 22.1 ND Neg G G 19.8 22.6 ND Neg G G 19.8 19.3 ND Neg G G 19.9 22.4 ND Neg G G 23.6 ND 25.6 Pos G G 24.1 Pos	19.09 21.7 ND Neg G G A 20.80 23.6 ND Neg G G A 21.42 ND 23.7 Pos G G A 21.42 ND 23.7 Pos G G A 21.7 24.7 ND Neg G G A 20.1 22.7 ND Neg G G A 17.6 20.1 ND Neg G G A 17.6 20.1 ND Neg G G A 19.8 22.6 ND Neg G G A 19.7 22.1 ND Neg G G A 18.8 19.3 ND Neg G G A 18.8 21.3 ND Neg G G T 23.6 ND 25.6 Pos G<

84	19.65	ND	21.96	Pos	G	G	Т	N501Y
85	14.29	ND	17.09	Pos	G	G	Т	N501Y
86	16.77	ND	19.95	Pos	G	G	Т	N501Y
87	21.30	ND	23.09	Pos	G	G	Т	N501Y
88	22.16	ND	23.75	Pos	G	G	Т	N501Y
89	20.03	ND	22.45	Pos	G	G	Т	N501Y
90	16.44	ND	18.46	Pos	G	G	Т	N501Y
91	14.93	ND	16.85	Pos	G	G	Т	N501Y
92	15.04	ND	16.86	Pos	G	G	Т	N501Y
93	16.38	ND	21.15	Pos	G	G	Т	N501Y
94	13.71	ND	15.44	Pos	G	G	Т	N501Y
95	17.89	ND	19.75	Pos	G	G	Т	N501Y
96	27.11	31.80	ND	Neg	G	G	А	Wild-type
97	28.46	32.66	ND	Neg	G	G	А	Wild-type
98	20.26	24.98	ND	Neg	G	G	А	Wild-type
99	26.55	31.17	ND	Neg	G	G	А	Wild-type
100	25.55	30.62	ND	Neg	G	G	А	Wild-type
101	20.63	25.58	ND	Neg	G	G	А	Wild-type
102	16.87	ND	19.57	Pos	G	G	Т	N501Y
103	16.04	ND	17.5	Pos	G	G	Т	N501Y
104	13.64	15.7	ND	Neg	G	G	А	Wild-type
105	21.50	22.9	ND	Neg	G	G	А	Wild-type
106	18.10	19.4	ND	Neg	G	G	А	Wild-type
107	18.16	19.4	ND	Neg	G	G	A	Wild-type
108	16.52	18.6	ND	Neg	G	G	А	Wild-type
97 98 99 100 101 102 103 104 105 106 107	28.46 20.26 26.55 25.55 20.63 16.87 16.04 13.64 21.50 18.10 18.10	32.66 24.98 31.17 30.62 25.58 ND ND 15.7 22.9 19.4 19.4	ND ND ND ND ND 19.57 17.5 ND ND	Neg Neg	G G G G G G G G G G G	G G G G G G G G G G	A A A A A A A A A A	Wild-ty Wild-ty Wild-ty Wild-ty Wild-ty N501Y Wild-ty Wild-ty Wild-ty Wild-ty

109	21.79	23.7	ND	Neg	G	G	Α	Wild-type
110	20.81	22.4	ND	Neg	G	G	A	Wild-type
111	19.32	20.9	ND	Neg	G	G	A	Wild-type
112	12.65	15.2	ND	Neg	G	G	A	Wild-type
113	21.08	23.4	ND	Neg	G	G	A	Wild-type
114	22.37	24.2	ND	Neg	G	G	A	Wild-type
115	19.81	21.9	ND	Neg	G	G	A	Wild-type
116	18.91	20.9	ND	Neg	G	G	A	Wild-type
117	20.64	23.6	ND	Neg	G	G	A	Wild-type
118	20.99	23.3	ND	Neg	G	G	A	Wild-type
119	17.45	19.9	ND	Neg	G	G	A	Wild-type
120	17.30	ND	20.0	Pos	G	G	Т	N501Y
121	20.92	ND	23.3	Pos	G	G	Т	N501Y
122	15.60	17.9	ND	Neg	G	G	A	Wild-type
123	32.45	34.2	ND	Neg	G	G	A	Wild-type
124	23.01	25.5	ND	Neg	G	G	A	Wild-type
125	25.93	28.1	ND	Neg	G	G	A	Wild-type
126	12.08	14.5	ND	Neg	G	G	A	Wild-type
127	13.66	16.3	ND	Neg	G	G	A	Wild-type
128	12.11	14.4	ND	Neg	G	G	A	Wild-type
129	23.63	25.4	ND	Neg	G	G	A	Wild-type
130	27.52	29.4	ND	Neg	G	G	A	Wild-type
131	24.40	ND	26.7	Pos	G	G	Т	N501Y
132	28.29	28.70	29.3	Mix	MIX base			MIX base
133	22.44	23.9	ND	Neg	G	G	A	Wild-type

101	2 1 2 1				~	â		*****
134	24.06	25.6	ND	Neg	G	G	A	Wild-type
135	18.42	20.7	ND	Neg	G	G	А	Wild-type
136	17.93	19.7	ND	Neg	G	G	А	Wild-type
137	23.90	ND	25.4	Pos	G	G	Т	N501Y
138	20.66	ND	22.9	Pos	G	G	Т	N501Y
139	27.82	ND	30.4	Pos	G	G	Т	N501Y
140	18.76	ND	20.8	Pos	G	G	Т	N501Y
141	15.49	ND	17.4	Pos	G	G	Т	N501Y
142	15.30	ND	17.5	Pos	G	G	Т	N501Y
143	16.07	ND	18.5	Pos	G	G	Т	N501Y
144	18.51	ND	21.0	Pos	G	G	Т	N501Y
145	14.70	ND	17.0	Pos	G	G	Т	N501Y
146	14.11	ND	16.7	Pos	G	G	Т	N501Y
147	18.9	ND	21.7	Pos	G	G	Т	N501Y
148	20.1	ND	22.4	Pos	G	G	Т	N501Y
149	18.7	ND	20.6	Pos	G	G	Т	N501Y
150	14.7	ND	15.8	Pos	G	G	Т	N501Y
151	11.9	14.5	ND	Neg	G	G	А	Wild-type
152	15.0	18.3	ND	Neg	G	G	А	Wild-type
153	32.2	36.2	ND	Neg	G	G	А	Wild-type
154	23.7	27.9	ND	Neg	G	G	А	Wild-type
155	20.8	24.1	ND	Neg	G	G	А	Wild-type
156	17.0	19.8	ND	Neg	G	G	A	Wild-type
157	34.5	36.0	ND	Neg	G	G	A	Wild-type
158	15.1	17.8	ND	Neg	G	G	A	Wild-type

159	10.9	13.5	ND	Neg	G	G	А	Wild-type
160	ND	37.9	ND	Neg	G	G	А	Wild-type

442 a.ND= Not Detected. Mix means probes for N501 and N501Y were detected when the specimen

443 was run in our assay and the Sanger sequencing results showed signals for both N501 and

444 N501Y.

445

446 Supplementary Table 2: Summary of intra-run repeatability

	Interpretation					
СТ		Average	SD	CV	interpretation	
20.2	20.19	19.96	20.12	0.136	0.007	N501Y Variant
28.99	28.69	28.57	28.75	0.216	0.008	Wildtype
Und ^a	Und	Und	NA	NA	NA	undetermined
29.43	29.49	29.38	29.43	0.055	0.002	N501Y Variant
24.96	25	24.85	24.94	0.078	0.003	N501Y Variant
Und	Und	Und	NA	NA	NA	undetermined
23.55	23.68	23.3	23.51	0.193	0.008	Wildtype
30.4	30.38	30	30.26	0.225	0.007	N501Y Variant
21.57	21.57	21.31	21.48	0.15	0.007	N501Y Variant
Und	Und	Und	NA	NA	NA	undetermined
23.82	23.59	23.77	23.73	0.121	0.005	Wildtype
22.93	23.03	22.98	22.98	0.05	0.002	N501Y Variant
28.99	29.11	28.59	28.9	0.272	0.009	N501Y Variant
Und	Und	Und	NA	NA	NA	undetermined

Und	Und	Und	NA	NA	NA	undetermined
24.35	24.36	24.06	24.26	0.17	0.007	Wildtype
29.96	30.05	30.05	30.02	0.052	0.002	Wildtype
24.21	24.35	24.03	24.2	0.16	0.007	N501Y Variant
30.36 ^b	29.84	30.46	30.22	0.333	0.011	N501Y Variant
30.49 ^b	30.12	30.3	30.3	0.185	0.006	Wildtype
29.73	28.9	28.97	29.2	0.46	0.016	N501Y Variant

a. Und: Undetermined (not positive for SARS-COV2)

b. Specimen with mixed population of N501 and N501Y.

477 Supplementary Appendix A:

478

479 PCR Amplification and Sequencing of Partial Spike Gene Methodology:

480 Primers were designed to amplify a 698 bp S gene fragment spanning the region of interest (genome positions:

481 22516 to 23214). Reverse transcription and amplification of the partial S gene was performed using the OneStep

482 RT-PCR kit (QIAGEN, Hilden, Germany). A 25 µl reaction mixture contained 5 µl of 5X QIAGENOneStep RT-

483 PCR Mix, 1 μl (200 μM) of dNTPs, 1 μl of OneStep RT-PCR enzyme mix, 1 μl of each forward (VOCF) and

484 reverse (VOCR) primers at a final concentration of 0.4 μM (**Supplementary Table 1**), 11μl of water and 5μl of

- 485 RNA. Reactions were carried out on the Applied Biosystems[™] SimpliAmp[®] Thermal Cycler (Thermo Fisher
- Scientific, Massachusetts, United States) with the following conditions: 1 cycle at 50 °C for 30 minutes and 1 cycle

487 at 95 °C for 15 minutes, followed by 40 cycles of amplification at 94 °C for 30 seconds, 56 °C for 30 seconds, and

- 488 72 °C for 1 minute, and a final extension cycle of 72 °C for 10 minutes.
- 489

490 Applied BiosystemsTM BigDyeTM Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific, Massachusetts,

491 United States) was used for bidirectional sequencing of PCR fragments following manufacturer's recommendations.

492 Each reaction contained 0.5 μl of Terminator Ready Reaction Mix, 3.75 μl of 5X buffer, 1μl of primer mix and 1 μl

amplified PCR product, and 13.75µl of water in a final volume of 20 µl. Default cycling conditions for the

BigDye[™] Terminator reaction were used as follows: 96°C for 1 minute followed by 35 cycles of 96°C for 10

495 seconds, 50°C for 5 seconds, and 60°C for 4 minutes. BigDye[™] reaction products were purified using an EDTA/

496 ethanol precipitation method and resuspended in 20µl Hi-Di[™] Formamide (Thermo Fisher Scientific,

497 Massachusetts, United States). Nucleotide sequences were determined using the Applied Biosystems[™] ABI 3130x1

498 Genetic Analyzer (Thermo Fisher Scientific, Massachusetts, United States) and analyzed using FinchTV software

499 (Geospiza, Inc.).